Leerink downgraded iTeos Therapeutics (ITOS) to Market Perform from Outperform with a price target of $9, down from $47, following the company’s and GSK‘s (GSK) decision to discontinue their Fc-competent anti-TIGIT, belrestotug, after their Phase 2 GALAXIES Lung-201 and Phase 2 GALAXIES H&N-202 studies failed to demonstrate clinically meaningful improvements over anti-PD-1 monotherapy. Given negative consensus on the TIGIT class and specific questions on belrestotug’s toxicity profile, the firm is not surprised that iTeos traded positively on the news of belrestotug’s termination and announced strategic review to “maximize shareholder value.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- iTeos Therapeutics downgraded to Market Perform from Outperform at Leerink
- Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth
- iTeos Therapeutics downgraded to Neutral at JPMorgan after TIGIT program ended
- iTeos Therapeutics downgraded to Neutral from Overweight at JPMorgan